Expert Insight into Emerging Treatments for EGFR TKI-Resistant NSCLC and HER2-Positive NSCLC

Target Audience
Medical oncologists, thoracic oncologists, pathologists, oncology nurse practitioners, oncology physician assistants, and other HCPs managing patients with NSCLC

Program Overview
Despite substantial advances in the management of non-small cell lung cancer (NSCLC) during the past decade, advanced NSCLC continues to have persistently low 5-year survival rates and imposes a significant burden on patients. Improved molecular-testing practices and integration of new data on targeted treatments could inform treatment decision-making and help clinicians optimize patient care.

Join a panel of experts from the thoracic oncology team to discuss the clinical relevance of HER2 and HER3 status in the treatment of NSCLC. Panelists will explore the identification of actionable mutations in patients with newly diagnosed NSCLC and review how to select appropriate assays for molecular testing. Experts will also look at the landscape of current and emerging targeted therapies and discuss how to account for individual clinical characteristics and mitigate potential adverse effects

Educational Objectives
After completing this activity, the participant should be better able to:

Illustrate appropriate testing to identify clinically relevant mutations
Appraise current and emerging targeted therapies for NSCLC, including mechanisms of action, key trial data, and strategies to manage potential side effects